BICMG

Business Information Consulting & Management Group

COVID-19 and the role of mobile health technology by Health Europa

iStock-metamorworks-1-1536x864.jpg

Mobile health technologies are a viable option in monitoring COVID-19 patients at home, and to predict who will need medical intervention, according to new research.

An international task force has conducted research that has revealed that mobile health technologies, such as wearable sensors, electronic patient-reported data, and digital contact tracing, can help with monitoring COVID-19 patients at home, and could also be used to monitor and predict coronavirus exposure in people presumed to be free of infection, providing information that could help prioritise diagnostic testing.

The 60-member panel, with members from the University of Massachusetts, Amherst, Australia, Germany, Ireland, Italy, Switzerland, and the US, was led by Harvard Medical School associate professor Paolo Bonato, director of the Motion Analysis Lab at Spaulding Rehabilitation Hospital in Boston. The research study, ‘Can mHealth Technology Help Mitigate the Effects of the COVID 19 Pandemic?’ has been published in the IEEE Open Journal of Engineering in Medicine and Biology.

Applying technology to COVID-19 care

The study found that smartphone applications that allow patients to self-report, along with wearable sensors enabling physiological data collection, could be used to monitor clinical workers and detect early signs of an outbreak in hospital or healthcare settings.

Within the community, early detection of COVID-19 cases could be achieved by building on research that showed it is possible to predict influenza-like illness rates, as well as COVID-19 epidemic trends, by using wearable sensors to capture heart rate and sleep duration, among other data.

Bonato said: “To be able to activate a diverse group of experts with such a singular focus speaks to the commitment the entire research and science community has in addressing this pandemic. Our goal is to quickly get important findings into the hands of the clinical community, so we continue to build effective interventions.”

Task force members Lee and Rahman, inventors of mobile health sensors themselves, reviewed 27 commercially available remote monitoring technologies that could be immediately used in clinical practices to help patients and frontline healthcare workers monitor symptoms of COVID-19.

Lee said: “We carefully investigated whether the technologies could ‘monitor’ a number of obvious indicators and symptoms of COVID-19 and whether any clearance or certification from health authorities was needed.

“We considered ease of use and integration flexibility with existing hospital electronic systems. Then we identified 12 examples of technologies that could potentially be used to monitor patients and healthcare workers.”

Bonato noted that additional research will help expand the understanding of how best to use and develop the technologies. “The better data and tracking we can collect using mHealth technologies can help public health experts understand the scope and spread of this virus and, most importantly, hopefully help more people get the care they need earlier.”

The paper concludes, ‘When combined with diagnostic and immune status testing, mHealth technology could be a valuable tool to help mitigate, if not prevent, the next surge of COVID-19 cases.’

Source: https://www.healtheuropa.eu/covid-19-and-the-role-of-mobile-health-technology/102246/

Medical tech trends accelerated by COVID-19 by John Murphy

The year 2020 is already halfway gone—and most of us will be glad to see it go altogether. Still, while COVID-19 has killed tens of thousands of Americans, put millions more Americans out of work, and ground the US economy to a standstill, it has also forced upon us innovations and processes that will make things better in the future. 

Thanks to the COVID-19 crisis, several emerging healthcare technologies are arriving sooner than later. 

What innovations and processes, you ask? Here are five emerging healthcare technology trends that may arrive sooner rather than later, thanks in part to coronavirus. 

Blockchain

You’ve probably read or heard the word “blockchain” before...but what is it exactly? Simply put, it’s a technology that provides a secure way to track transactions. “More specifically, blockchain is a shared, immutable record of peer-to-peer transactions built from linked transaction blocks and stored in a digital ledger,” according to a white paper by Deloitte Consulting LLP.

Hmm, sounds like no big deal, right? Actually, it is a big deal. Had blockchain been in widespread use in the first months of the COVID-19 outbreak, the US healthcare system probably wouldn’t have run so short on ventilators, masks, and other personal protective equipment. 

“Blockchain is excellent at tracking the chain of custody of an item from manufacturer to the hospital and then eventually to its end use—the patient. It gives visibility into item usage and movement,” John Kupice, CEO of H-Source, explained to Supply & Demand Chain Executive magazine. “Blockchain has the potential to streamline the supply chain and facilitate FDA recall and drug track-and-trace requirements, as well as increase efficiency, reduce waste and reduce risk profiles.”

Besides keeping close track of supplies, blockchain can provide a number of other important functions in healthcare—notably, a secure, reliable database of patient health information that’s commonly shared by a wide range of entities, such as physician practices, hospital systems, insurers, government agencies, and others. There are still a number of barriers to this, but if (or rather when) it is implemented, it would save everyone enormous amounts of time and prevent a host of errors. 

In addition, a portion of this data could be made available to provide a rich set of standardized, non-patient identifiable information for use in widescale clinical studies. 

Data sharing

While blockchain would provide one mechanism for data sharing, the process of data sharing itself is a powerful health tech trend. In fact, data sharing is government-mandated by the 21st Century Cures Act, which was passed in December 2016 and stipulated new data-sharing rules for electronic health records (EHR) systems. 

These rules, which have only recently been finalized, “promote standardized language and application programming interfaces (APIs) that encourage technical interoperability across EHR systems,” according to a 2020 health trends report from Stanford Medicine. The rules also widely expand patients’ access to their own medical records and limit information-blocking practices.

“For an industry that has long struggled with low levels of information sharing and poor interoperability across its technology systems, in 2020 we expect to see the final rules create a seismic shift in how health care stakeholders share and interact with digital medical records,” wrote the authors of the Stanford report. 

Another use of data sharing is for creating “Big Data,” which can help predict specific illnesses both in individuals and in large populations. Here’s just one example: Researchers used EHR data to predict the early risk of chronic kidney disease in patients with diabetes. “[T]he predictive power of our real world data-based model for diabetes-related chronic kidney disease outperforms published algorithms, which were derived from clinical study data,” the study authors wrote. 

Artificial intelligence 

Artificial intelligence (AI) is already being used in medicine. During the COVID-19 pandemic, one of the things that has helped, in a small way, to reduce demands on the healthcare workforce is the use of chatbots. Now found on health insurance company websites (as well as shopping sites, fast-food sites, and many others), chatbots are AI-powered applications that can simulate a natural human conversation to provide patient (or customer) assistance.

Besides simple chatbots, AI applications have been developed to perform all sorts of high-level tasks, such as scanning medical images to identify potential cancers and tumors. AI is also being used for analyzing data in pathology, lab tests, genetics, and other clinical areas to accelerate processing and help facilitate decision-making and diagnoses.

It’s important to note that AI itself doesn’t make the diagnosis. Rather, it helps the clinician to make a more informed diagnosis. To underscore this point, some authors from the National Academy of Medicine suggested the term “augmented intelligence” in a publication about AI in healthcare.

“The opportunity for augmenting human cognition is vast, from supporting clinicians with less training in performing tasks currently limited to specialists to filtering out normal or low-acuity clinical cases so specialists can work at the top of their licensure,” wrote the National Academy of Medicine authors. “Additionally, AI could help humans reduce medical error due to cognitive limits, inattention, micro-aggression, or fatigue. In the case of surgery, it might offer capabilities that are not humanly possible.”

Still, many questions must still be answered about the implementation of artificial intelligence, “including what role AI should have in the patient-doctor relationship, ethical considerations, and, more practically, how it can best alleviate clinical practice burdens,” noted the authors of the Stanford Medicine report.

Wearables 

FitBit and Apple Watch are two well-known wearable healthcare monitors (“wearables”) that can tell you your activity level, your heart rate, or (in the Apple Watch) warn you of signs of atrial fibrillation. 

But, many other wearables and biosensors are now available or coming soon, like a contact lens that monitors blood glucose levels in people with diabetes or a “smart” ring that can detect COVID-19 symptoms up to 3 days in advance. 

Wearables could be used by physicians to remotely monitor patients’ health, helping to provide more data on a patient’s condition or earlier detection of illness or health emergency. 

Physicians themselves are early adopters to this technology; nearly half of physicians, residents, and medical students use a wearable, compared with one-third of the general US population, according to the Stanford Medicine report. Importantly, among the physicians, residents, and medical students who use wearables, roughly two-thirds use the data from their devices to make personal healthcare decisions. These findings suggest that physicians are on their way to implementing wearables on a larger scale with their patients. 

5G

All this technology comes at a cost—and not just the cost of developing and implementing it, but the data demands on bandwidth. The answer to better data communication: 5G. 

What exactly is 5G? It’s fifth-generation wireless network technology that’s up to 10 times faster than the existing 4G LTE network. 5G can also handle more connected devices at the same time, and can make connecting with servers and cloud platforms faster and easier. 

As doctors around the country have now experienced, telemedicine works best with fast and reliable internet service. 5G will deliver on the long-awaited promise of more effective, reliable, and user-friendly telemedicine. 

On 5G, you can better send and receive large image files—like a high-def 3D MRI scan—to easily share with a specialist for a remote consultation. 5G will also facilitate the delivery of treatments through virtual reality, and make remote patient monitoring easier and more reliable.

Although it will take several years for a nationwide 5G infrastructure to be established in the United States, 5G networks are now being rolled out in a number of cities and regions. Already in 2020, several Android smartphone manufacturers have released 5G-enabled devices, and Apple is expected to release a 5G iPhone in the fall. 

Source: https://www.mdlinx.com/article/medical-tech-trends-accelerated-by-covid-19/72Nt3cXT96dcZuxXIcOr8v

Medical robotics in China: the rise of technology in three charts by Sarah O'Meara

4.jpg

In 2006, China highlighted the importance of robotics in its 15-year plan for science and technology. In 2011, the central government fleshed out these ambitions in its 12th five-year plan, specifying that robots should be used to support society in a wide range of roles, from helping emergency services during natural disasters and firefighting, to performing complex surgery and aiding in medical rehabilitation.

Guang-Zhong Yang, head of the Institute of Medical Robotics at Shanghai Jiao Tong University, says that China’s robotics research output has been growing steadily for two decades, driven by three major factors: “The clinical utilization of robotics; increased funding levels driven by national planning needs; and advances in engineering in areas such as precision mechatronics, medical imaging, artificial intelligence and new materials for making robots.”

Yang points out that funding levels for medical robotics from the National Natural Science Foundation of China and the Ministry of Science and Technology began to increase more sharply in 2011 compared to the previous decade.

3.jpg



The accompanying rises in research output are closely related to the introduction of specialized robotics equipment in medical-research facilities, says Yao Li, a research scientist at Stanford Robotics Laboratory in California and founder of the company Borns Medical Robotics, based in both Chengdu, China, and Silicon Valley, California.

Between 1999 and 2019, the number of papers published by at least one Chinese author in the combined fields of biomedical engineering and robotics increased from 142 to 4,507, and spiked twice during that period (see ‘Published papers’), according to data from the Web of Science. One peak was in 2008, two years after a robotic system for minimally invasive operations called da Vinci was first deployed to hospitals in China. The second was in 2017, a year after the first Chinese-designed robot for minimally invasive spinal surgery was approved for sale.


2.jpg

In 2019, the number of da Vinci systems installed in Chinese hospitals that year leapt to 59, up from only 8 installations in 2018 (see ‘Spike in hospital robotics’). This surge followed a 2018 government push to encourage research on robotics technology and its clinical application, according to Jian-Kun Hu, director of the department of gastrointestinal surgery at West China Hospital in Chengdu. The central government’s plan included an intention to purchase 154 new surgical robot systems by the end of 2020, and a breakdown of how the systems would be allocated nationwide (see ‘Surgical robots across China’).

Source: https://www.nature.com/articles/d41586-020-01795-7

A multimodal novel lensless microscopy technology for medical applications by Annette Lochner

Today's state-of-the-art analysis of biological samples by light microscopy includes a vast variety of techniques ranging from conventional bright field microscopy and phase contrast microscopy to high resolution confocal laser scanning microscopy and to recently developed super resolution microscopy techniques like stimulated emission depletion (STED) or stochastic optical reconstruction microscopy (STORM) which abnegate Abbe's limit of diffraction.

Despite the availability of these sophisticated, super resolution techniques, reproducible visualization of cells and identification of subcellular structures in biological samples still requires staining with dyes or immunolabeling by antibodies to specific cellular antigens.

Generally, in-vitro observation of living cells can provide valuable insights into their structure and dynamics including organization of organelles and transduction of chemical signals involved in cell-cell and cell-matrix interactions. Unfortunately, there is a limited use for long term in-vitro imaging as most high-resolution microscopy technologies require processed/fixed tissues or cells. As both high resolution optical microscopy and fluorescence imaging usually require highly skilled users, expensive equipment and maintenance, the presented novel digital in-line holographic microscopy (DIHM) in-vitro imaging technology opens a vast field of applications for standard users. This analytical optical system offers quick and reproducible results at low costs. Moreover, it voids the necessity of referral to specialized labs and is easily implemented as a diagnostic tool for doctors (general practitioners and specialists).

DIHM is based on the numerical reconstruction of a digitally recorded hologram. It allows for the acquisition of both, the amplitude and phase information of a wave front shaped by the microscopic sample. The advantage of the DIHM lies in the simplicity of its setup: the microscope consists of a light-emitting diode (LED) as an illumination source, appropriate filtering for coherence enhancement and an image sensor. The comprehensive data processing algorithm transforms the recorded holograms into a microscope image by angular spectrum approach and digital filtering. In general, the resolution of such a microscope is strongly influenced by the spatial coherence length of the illumination, which can be enhanced via reducing the emitting area, either by cutting a part of the wave front with the pinhole or by use of a point-like nanoLED. The nanoLED arrays developed within the EU Horizon 2020 program ChipScope project will allow enhancement of the imaging resolution compatible to the conventional optical microscopy.

Lensless DIHM microscope

This fact makes lensless microscopy an ideal tool for medical diagnosis in remote areas since there is no need for the medical doctor to bring and maintain large, heavy and sensitive analysis devices. A simple laptop and a suitcase sized lensless microscope assembly is enough to—for example—make a parasite diagnosis from body fluid samples (e.g. Malaria, Amoeba etc.). The robust construction enables a fast, reliable and automated analysis of the specimen by combining not only high-resolution light microscopy but also implementing modern analysis techniques based on the detection of changes in human DNA, identifying viral genomes and immunological characterization in one device.

To provide the highest light sensitivity and optical resolution, the system is equipped with a normal grayscale camera to work in a multi-cell imaging bright field mode. This novel lensless microscope is equipped with a microfluidic flow channel system for handling living cells and imaging.

Source: https://phys.org/news/2019-10-multimodal-lensless-microscopy-technology-medical.html

Once Again, Medical Technology Industry Pushes To Derail The Device Tax by Bruce Japsen

1.jpg

Yet again, the medical technology industry is pushing for a permanent end to a medical device tax they’ve worked with Congress to shelve for almost five years now.

The 2.3% tax on medical device sales that is part of the Affordable Care Act has already been on temporary hiatus since the beginning of 2016 but is scheduled to return at the end of this year.

“(The device tax) has now been off the books longer than it’s been on the books,” Scott Whitaker CEO of The Advanced Medical Technology Association (AdvaMed) said Monday afternoon at the annual medical technology meeting in Boston. AdvaMed represents hundreds of medical device makers, including Abbott Laboratories, Johnson & Johnson, Medtronic and Stryker.

Before the device tax was put on hiatus, the IRS collected between $1 billion and $2 billion a year in 2013, 2014 and 2015. But Congress continues to provide the industry with a temporary fix, usually as budgets or spending packages are being negotiated at the end of the year or near the end of a Congressional session.

Now the medical device industry is escalating its push to see the tax permanently repealed and said there are 247 co-sponsors in the U.S. House of Representatives to do that and 34 members of the U.S. Senate including 10 Democrats.

The Joint Committee on Taxation has said repealing the medical device tax would cost the U.S. Treasury about $20 billion over a decade. Yet the industry has successfully convinced members of Congress over time at the harm the tax could do to employment and innovation.

Just last week, medical device makers earned a key ally in the U.S. Senate when Republican Sen. Rick Scott of Florida agreed to co-sponsor the Protect Medical Innovation Act, which would permanently repeal the device tax. AdvaMed said eliminating the tax will boost medtech businesses that account for almost 21,000 jobs in Florida and nearly 2 million jobs in the U.S.

Though a permanent repeal gains momentum, medical device makers are realistic in how Congress operates. “The likelihood of full repeal is fairly low,” Stryker chairman and CEO Kevin Lobo, who is chair of AdvaMed’s board, said Monday, adding that he is hoping for a multi-year suspension of the device tax.

Whitaker said an end-of-the year fix is more likely as Congress votes on major legislation and packages of legislation. “It’s not the way it should work but that’s the reality and how Congress works,” Whitaker said.

Source: https://www.forbes.com/sites/brucejapsen/2019/09/23/once-again-medical-technology-industry-pushes-to-derail-the-device-tax/#6360b6d22b34

Smart Medtech Forum Focuses on Innovation, Future of Medical Technology by Printed Electronics Now

1.jpg

Cutting-edge medical technology will highlight SEMICON Europa (Nov. 12-15, 2019 at Messe München, Munich, Germany), as the SMART MedTech Forum gathers industry experts for insights into the latest developments and trends in medtech innovations driven by semiconductors.

SEMICON Europa registration is open for visitors and exhibitors.

The SMART MedTech Forum takes the stage at the Inspiration Hub (Hall B2), where attendees will connect with companies behind medtech innovations, experience leading medtech products, and discover startups shaking up the healthcare scene. The forum features the following sessions focused on the critical role of semiconductors and medtech in enabling technology innovation and solutions to the world’s most pressing healthcare challenges.

Global Healthcare Solutions
Janssen Pharmaceutical Companies of Johnson & Johnson will kick off the forum with a discussion on global healthcare challenges and opportunities, followed by a MedTech Europe presentation on trends in healthcare, medtech and digital technology. imec and GE Research will explore how to bridge the gap between semiconductors and medical technologies to solve global healthcare challenges.

Digitization of Preventive Healthcare
More smart medtech device companies are focused on preventive medicine, setting the stage for a presentation by OnePlanet Connected Health Solutions on opportunities in digital health for tracking mental stress using wearable data and machine learning. Maxim Integrated will discuss the potential of sleep monitoring to prevent health problems and reduce healthcare costs, and how wearables can help prevent high blood pressure. And ams AG will examine how sensors can enable consumer health applications for preventative healthcare.

Revolutionizing Healthcare with Personalized Medicine
Personalized medicine is on the rise as it aims to increase the efficiency and quality of care through customized patient management. Yole Developpement and Fraunhofer EMFT will introduce innovative solutions in precision medicine and drug delivery for personalized healthcare, while X-FAB will discuss how MEMS manufacturing is enabling breakthroughs in personalized medicine.

The Digital Patient: The Future of Artificial Organs and Human Avatars
Digital patients promise to prevent and cure disease and transform healthcare through personalized treatment. Experts from the EPFL Lausanne, Philips, Robert Bosch GmbH, and Bart's Heart Centre will discuss quantum leaps in personalized treatment, including the use of artificial organs, Organ-on-Chip, and human avatars as the next paradigm in healthcare.

Pioneering Research in Medical Technologies
With fundamental research key to healthcare innovation, leading research and innovation centers imec and the KU Leuven will examine how CMOS-compatible technologies and systems can be applied to life sciences to enable platforms for personalized medicine.

Other SMART MedTech Forum Highlights
The MedTech Startup Session will host some of the most innovative medtech startups, including Sensome and its breakthrough remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. Onera Health and ChronoLife will introduce innovative diagnostic solutions, while PKvitality will present its health-monitoring smartwatches. IC’Alps will showcase its products and services for the design and supply of ASIC/SOC integrated circuits for medtech applications.

In addition, leaders from ChronoLife, the European Commission and Siemens Healthineers will gather for the panel Key Drivers Transforming Healthcare: AI, Big Data and Cybersecurity, three areas central to medtech advances.

Source: https://www.printedelectronicsnow.com/contents/view_breaking-news/2019-09-12/smart-medtech-forum-focuses-on-innovation-future-of-medical-technology/

High medical costs have driven these people to put their health at risk by Darla Mercado and John W Schoen

The cost of care has become so onerous that some people have ditched going to the doctor altogether.

To save on health care, a third of people aged 25 to 45 avoided seeing a medical professional, hoping instead that their condition will eventually resolve, according to data from the Nationwide Retirement Institute.

The institute performed an online poll of 1,000 adults in that age cohort in July.

Close to 3 in 10 of the participants said they considered not seeking care to avoid their high deductibles, while more than 20% said they stretched their prescription drugs by taking less than the recommended dosage.

“Health care is one of the top reasons why people go into bankruptcy,” said Kristi Rodriguez, leader of the Nationwide Retirement Institute.

Indeed, a March 2019 study in the American Public Journal of Health found that about two-thirds of all bankruptcies were related to medical problems.

Annually, 530,000 families file for bankruptcy due to health-care issues and bills, according to the research.

While employers chip in a substantial amount of premium contributions for workplace health plans, workers are still on the hook for a big portion.

In 2018, employers paid an average of $15,159 in premiums to cover a family of four, according to data from the Kaiser Family Foundation.

Meanwhile, workers paid an average of $4,706 in premiums to provide coverage to their families and they spent an average of $3,020 in out-of-pocket expenses, including meeting deductibles, copayments and coinsurance.

Employers have sought to share more costs with workers through high-deductible health plans.

Close to 9 out of 10 employers anticipate offering these plans next year, according to data from the National Business Group on Health.

These plans typically are paired with a health savings account (HSA) — where workers can save tax-deductible or pretax dollars, have them grow free of tax and then withdraw them tax-free for qualified medical expenses.

People with single coverage can contribute up to $3,550 in 2020, while participants with family coverage can sock away up to $7,100.

Bear in mind, these plans generally come with higher consumer costs before coverage kicks in.

The IRS defines a high-deductible plan in 2020 as having an annual deductible of at least $1,400 for self-only coverage or $2,800 for family plans.

Only 17% of people polled by Nationwide said they participate in HSAs.

Among those who have an HSA, 25% use it to cover current health-care costs, rather than allowing the balance to accumulate year over year, Nationwide found.

“There is a clear opportunity for further education around and greater adoption of HSAs among younger and older adults,” said Rodriguez

Source: https://www.cnbc.com/2019/09/06/how-medical-expenses-push-these-people-to-put-their-health-at-risk.html

For sale: med tech malware in the latest Medical Technology by Medical Device Network

Medical Technology is now available on all devices! Read it here for free in the web browser of your computer, tablet or smartphone. 

The rise of medical devices has forced medical authorities to rapidly reevaluate their processes as innovation continues to outpace regulation. We take a look back at some of the most notable developments in med tech, including a new method to grow bone from stem cells and a breakthrough in wireless charging for implants.

Also, we review the biggest stories from this year, including Silicon Valley Bank’s initiative to fund med tech innovation from the ground up, an innovative molecular imaging instrument that could help nip drug failure in the bud, and round up key machine learning developments in the medical field.

Plus, we find out how healthcare providers can realise the vision of connected healthcare delivery by capitalising on the second wave of digitisation, profile disposable diagnostics tools helping to address the growing problem of antimicrobial resistance, and explore the super-sized medical device sector in Costa Rica.

Finally, we take a look at the challenge of regulating 3D printed medical devices and ask if hospitals should eschew single use tools and focus on reusing more medical devices as a cheap and safe alternative to buying expensive new equipment.

In this issue

Under the skin: the medical device industry and the dark web

Medical companies are some of the organisations most frequently targeted by cybercriminals, often using malware tools traded on the dark net, with 24% of dark web vendors offering access to the healthcare vertical market according to a University of Surrey report. But just how deep does the rabbit hole go? Chloe Kent investigates.

AI and open sourcing: a new frontier for prosthetic leg design

Open-source projects allow clinicians to piggyback off of each other’s research and create the best artificial limbs possible. Scientists from the University of Michigan have now unveiled an artificially intelligent prosthetic leg that fellow researchers can access through open-sourcing, a development which has the potential to revolutionise the prosthetic leg industry. Chloe Kent reports.

The age of the autonomous pharmacy

Omnicell UK recently launched its vision for the ‘Autonomous Pharmacy’, a future where medication is managed digitally in cloud-based, AI powered systems, freeing pharmacists from administrative tasks in order to spend more time with patients. Abi Millar finds out more.

Q&A: Lifebank on the challenge of getting blood from A to B in Nigeria

In Nigeria, getting blood to a patient in need is a race against the clock, but the LifeBank app is revolutionising the way that blood is transported. Abi Millar finds out more about how LifeBank is speeding up blood deliveries, mobilising blood donations and saving lives.

5G meets medicine: separating fact from fiction

5G has been hailed as the next frontier for medicine, introducing new remote surgery capabilities and expanding patient access to the internet in hospitals. But not everyone is convinced. Chloe Kent takes a

Meril Life Sciences: leading a growing Indian medtech sector

India’s medical device sector is undergoing a drastic transformation, with a new regulatory regime aimed at luring industry backers and priming it for significant growth. Meril Life Sciences, one of the country’s medtech leaders, tells Chloe Kent how the changing industry is shaping its business.

Making electronic health records work

Electronic health records are now part of everyday healthcare, but few would claim they have reached their full potential, and for doctors, they have added an extra layer of administrative hassle. How can this time be cut down and the full range of benefits unlocked? Abi Millar reports.

Snooze, you lose: the devices helping to understand the science of sleep

Failure to sleep between seven and nine hours a night is associated with a long list of physical and mental health problems, yet three quarters of UK adults reportedly sleep less than that. Now, medical device manufacturers are trying to unlock the science of sleep to help consumers catch a few more crucial hours of shut-eye. Chloe Kent reports.

https://www.medicaldevice-network.com/features/for-sale-med-tech-malware-in-the-latest-medical-technology/

New immunotherapy shows promise against brain tumors in mice by Catharine Paddock

For the first time, scientists have shown that a new type of immunotherapy can reach and treat brain cancer from the bloodstream in mice. The nano-immunotherapy stopped brain tumor cells multiplying and increased survival.

Scientists who devised an immunotherapy that can cross the blood-brain barrier in mice hope that the findings may one day translate to humans.

The researchers believe that the new treatment could be the key to improving survival in people with glioblastoma, the most common and aggressive type of brain cancer.

Checkpoint inhibitors are drugs that help the immune system fight cancer. In the new immunotherapy, the drugs can remove a mechanism that enables the brain tumor to withstand attack from cancer-killing cells.

The blood-brain barrier is a unique feature of the vessels that supply blood to the brain and the rest of the central nervous system. The barrier stops potentially harmful toxins and pathogens from entering brain tissue from the bloodstream.

To date, promising types of immunotherapy that have passed clinical trials have not been very successful at crossing the blood-brain barrier.

"Although our findings were not made in humans," says senior study author Julia Y. Ljubimova, a professor of neurosurgery and biomedical sciences at Cedars-Sinai Medical Center in Los Angeles, CA, "they bring us closer to developing a treatment that might effectively attack brain tumors with [systemic] drug administration."

Using drugs that can treat the brain systemically — that is, by using the bloodstream to deliver them — would be an advantage over treatments that only work when doctors inject them directly into brain tissue.

The new study is also the first to describe an immunotherapy that can stimulate immune systems both throughout the body and local to the tumor in mice.

An aggressive brain cancer

Although they only represent a small percentage of cancer cases, brain cancers account for a disproportionate number of deaths.

According to the National Cancer Institute, which is one of the National Institutes of Health (NIH), an estimated 23,820 people in the United States will find out that they have brain cancer in 2019, and 17,760 will die of the disease in this same year.

Source: https://www.medicalnewstoday.com/articles/326220.php

When Apps get Your Medical Data, Your Privacy May Go With It by Natasha Singer

111.jpg

Americans may soon be able to get their medical records through smartphone apps as easily as they order takeout food from Seamless or catch a ride from Lyft.

But prominent medical organizations are warning that patient data-sharing with apps could facilitate invasions of privacy — and they are fighting the change.

The battle stems from landmark medical information-sharing rules that the federal government is now working to complete. The rules will for the first time require health providers to send medical information to third-party apps, like Apple’s Health Records, after a patient has authorized the data exchange. The regulations, proposed this year by the Department of Health and Human Services, are intended to make it easier for people to see their medical records, manage their illnesses and understand their treatment choices.

Yet groups including the American Medical Association and the American College of Obstetricians and Gynecologists warned regulators in May that people who authorized consumer apps to retrieve their medical records could open themselves up to serious data abuses. Federal privacy protections, which limit how health providers and insurers may use and share medical records, no longer apply once patients transfer their data to consumer apps.

The American Medical Association, the American Hospital Association and other groups said they had recently met with health regulators to push for changes to the rules. Without federal restrictions in place, the groups argued, consumer apps would be free to share or sell sensitive details like a patient’s prescription drug history. And some warned that the spread of such personal medical information could lead to higher insurance rates or job discrimination.

“Patients simply may not realize that their genetic, reproductive health, substance abuse disorder, mental health information can be used in ways that could ultimately limit their access to health insurance, life insurance or even be disclosed to their employers,” said Dr. Jesse M. Ehrenfeld, an anesthesiologist who is the chair of the American Medical Association’s board. “Patient privacy can’t be retrieved once it’s lost.”

Enabling people to use third-party consumer apps to easily retrieve their medical data would be a milestone in patient rights.

“Patient privacy can’t be retrieved once it’s lost,” said Dr. Jesse M. Ehrenfeld, the chair of the American Medical Association’s board.CreditDavid Kasnic for The New York Times

Dr. Don Rucker, the federal health department’s national coordinator for health information technology, said that allowing people convenient access to their medical data would help them better manage their health, seek second opinions and understand medical costs. He said the idea was to treat medicine as a consumer service, so people can shop for doctors and insurers on their smartphones as easily as they pay bills, check bus schedules or buy plane tickets.

“This is major, major, major,” he said. “The provision of health care will be brought into the app economy and, through that, to a much, much higher degree of patient control.”

The new rules are emerging just as Amazon, AppleGoogle and Microsoft are racing to capitalize on health data and capture a bigger slice of the health care market. Opening the floodgates on patient records now, Dr. Rucker said, could help tech giants and small app makers alike develop novel consumer health products.

The regulations are part of a government effort to push health providers to use and share electronic health records. Regulators have long hoped that centralizing medical data online would let doctors get a fuller, more accurate picture of patient health and help people make more informed medical choices, with the promise of better health outcomes.

In reality, digital health records have been cumbersome for many physicians to use and difficult for many patients to retrieve.

Americans have had the right to obtain copies of their medical records since 2000 under the federal Health Insurance Portability and Accountability Act, known as HIPAA. But many health providers still send medical records by fax or require patients to pick up paper or DVD copies of their files.

The new regulations are intended to banish such bureaucratic hurdles.

Dr. Rucker said it was self-serving for physicians and hospitals, which may benefit financially from keeping patients and their data captive, to play up privacy concerns.

“All we’re saying is that patients have a right to choose as opposed to the right being denied them by the forces of paternalism,” he said.

Dr. Don Rucker of the Department of Health and Human Services said it was self-serving for doctors and hospitals to play up privacy concerns.CreditDepartment of Health and Human Services

The Department of Health and Human Services proposed two new data-sharing rules this year to carry out provisions in the 21st Century Cures Act, a 2016 law designed to speed medical innovation.

Dr. Rucker’s office developed the one that would allow patients to send their electronic medical information, including treatment pricing, directly to apps from their health providers. It will require vendors of electronic health records to adopt software known as application programming interfaces, or A.P.I.s. Once the software is in place, Dr. Rucker said, patients will be able to use smartphone apps “in an Uber-like fashion” to get their medical data.

To foster such data-sharing, a coalition of tech giants — including Amazon, Google and Microsoft — has committed to using common standards to categorize and format health information. Microsoft, for instance, has developed cloud services to help health providers, insurers and health record vendors make data available to patients.

“What that lets an individual consumer do is to connect an app or service of their own choice into their health care records and pull down data about their historical lab tests, about their medical problems or condition, about medication prescription,” said Josh Mandel, chief architect for Microsoft Healthcare.

The other proposed rule, developed by the Centers for Medicare and Medicaid Services, would require Medicare and Medicaid plans, and plans participating in the federal health insurance marketplace, to adopt A.P.I.s so people could use third-party apps to get their insurance claims and benefit information. 

The regulations are expected to become final this year. Health providers and health record vendors will have two years to comply with the A.P.I. requirements. Electronic health record vendors that impede data-sharing — a practice called “information blocking” — could be fined up to $1 million per violation. Doctors accused of information blocking could be subject to federal investigation.

Brett Meeks, vice president of policy and legal for the Center for Medical Interoperability, a nonprofit that works to advance data sharing among health care technologies, said it would be better for regulators to help foster a trustworthy data-sharing platform before requiring doctors to entrust patients’ medical records to consumer tech platforms.

“Facebook, Google and others are currently under scrutiny for being poor stewards of consumer data,” he said. “Why would you carte blanche hand them your health data on top of it so they could do whatever they want with it?”

Tech executives are promoting data-sharing in health care. From left, Taha Kass-Hout of Amazon, Aashima Gupta of Google and Peter Lee of Microsoft attended a conference in July for Medicare’s Blue Button system.CreditMicrosoft

Physicians’ organizations and others said the rules failed to give people granular control over their data. They added that the regulations could require them to share patients’ sensitive medical or financial information with apps and insurers against their better judgment.

The current protocols for exchanging patients’ data, for instance, would let people use consumer apps to get different types of information, like their prescription drug history. But it is an all-or-nothing choice. People who authorized an app to collect their medication lists would not be able to stop it from retrieving specific data — like the names of H.I.V. or cancer drugs — they might prefer to keep private.

Dr. Rucker said that current information-sharing standards could not accommodate granular data controls and that privacy concerns needed to be balanced against the benefits of improved patient access to their medical information.

In any case, he said, many people are comfortable liberally sharing personal health details — enabling, say, fitness apps to collect their heart rate data — that are not covered by federal protections. Patients, he said, have the right to make similar choices about which apps to entrust with their medical data.

“A lot of this actually will be enforced by people picking apps they trust from brand names they trust in exactly the same way that people don’t let their banking data and their financial data just go out randomly,” he said.

Apple’s Health Records app, for instance, lets people send a subset of their medical data directly to their iPhones from more than 300 health care centers. Apple said it did not have access to that information because it was encrypted and stored locally on people’s personal devices.

But even proponents of the new regulations are calling for basic privacy and security rules for tech platforms that collect and use people’s medical information.

“The moment our data goes into a consumer health tech solution, we have no rights,” said Andrea Downing, a data rights advocatefor people with hereditary cancers. “Without meaningful protections or transparency on how data is shared, it could be used by a recruiter to deny us jobs,” or by an insurer to deny coverage.

Source: https://www.nytimes.com/2019/09/03/technology/smartphone-medical-records.html

Implanted Medical Devices and Vulnerabilities to Hackers by Jagger Esch

One newer security concern involves implanted medical devices and vulnerabilities to hackers. As it stands, about 10–15 devices are connected across the nation. Most of these are vulnerable to hackers, especially pacemakers and other implants, which are leaving patients at risk for attack.

Many medical devices use radio and/or network technology to share patient data among healthcare professionals. While this practice increases positive results for patients, it is also potentially dangerous, because many of these technologies lack adequate security, and several attacks have already taken place. By hacking cardiac defibrillators and pacemakers, attackers have already stolen sensitive medical records. The U.S. government is looking for ways to stop attacks on medical devices.

In October 2018, a report was filed by an inspector general on the FDA’s plans. The findings were “deficient for addressing medical device cybersecurity compromises.” In response, the FDA said it has “worked proactively” on the topic.

Learn more about device security at MTI’s upcoming conference,  Medical Device Cybersecurity: Legacy Device Remediation, Compensating Controls & End of Life | September 26–27, 2019 | Cambridge, MA or attend virtuallyThe rise of the digital age has raised security concerns regarding medical devices has put many on alert.
What are the risks? How much damage can hackers cause with such attacks?

As medical technology has evolved, implant devices are able to communicate wirelessly and the Internet of Things has introduced new possibilities with many wearable devices. These devices allow patients and their healthcare providers to stay connected. Although this sounds like great news, significant security vulnerabilities have been uncovered with some of these products.

Vulnerabilities to Hackers

Let’s face it, the more vulnerable the medical device, the higher its risk for hacking. In March 2019 Medtronic made headlines after disclosing a security flaw in some of its implantable devices.

Following the Department of Homeland Security’s flagging of a “critical cyber security weakness“, a vulnerability rating of 9.3 (out of 10 points) was given for one of its cardiac devices.

Medtronic’s cardiac devices use a wireless communication system. The system’s flaws could allow for potential access from unauthorized users. This means unauthorized users could change the device’s settings or at-home monitoring systems.

A few years ago, FDA recalled 465,000 implantable pacemakers manufactured by St. Jude Medical due to the potential for attacks. Patients with the implants didn’t have them taken out; instead, Abbott (owner of St. Jude Medical) released a firmware update in August 2017. The update includes more precise security for patients. The possible risks from attacks include hackers wearing down the device’s battery life or changing the heartbeat of a patient. These are both potentially fatal attacks.

Although, no such attack is on record—the threat is real.

This sounds horrifying, but it might not be as bad as it seems. These attacks would need to be made in close range to the patient. Also, it would have to occur during a time when the device connects to the internet to send or receive data. The risk is a long shot; however, it’s still a risk.

The True Safety

Fortunately, experts report that the security posture of the medical device company community has been working to improve this issue for the last few years.

The government has made improving medical device security a priority, according to Anura Fernando, UL’s Chief Innovation Architect of Medical Systems Interoperability & Security.

“The FDA is preparing new and improved guidance. The Healthcare Sector Coordinating Council recently put out the Joint Security Plan. Standards Development Organizations are evolving standards and creating new ones where needed. DHS is continuing to expand upon their CERT programs and other critical infrastructure protection plans, and the healthcare community is expanding and engaging with other to continuously improve upon the cybersecurity posture to keep pace with the changing treat landscape.” – Anura Fernando, as quoted in an article on How-To Geek

Although stakeholders are actively working to improve security in medical devices, there’s still a lot of work to be done.

Has Medical Device Security Improved?

Over the last few months, some security issues have surfaced regarding healthcare. From the outdated Windows platforms most healthcare providers rely on, to the outdated systems medical devices use—it’s time for an update. However, healthcare is increasing the number of connected medical devices and at a steady rate, and this means the opportunity for attacks are higher, too. Likewise, this makes detecting and scaling security more challenging.

Recent research from Forescout and Duo Security finds healthcare is resource constrained. The gaps in IT staffing are making it challenging for organizations to make the switch to platforms with more security.

Cynerio CEO and Founder Leon Lerman has seen a substantial increase on medical device security awareness over the last six months, according to an article on SecurityWeek.

More requests for projects that focus solely on the security of medical devices and looking for solutions to security breaches is very important to the telehealth community.

The title of “medical device security engineer” has also been evolving. Lerman stated this newer position is a mixture of IT, security and a biomedical engineer. Leaders from each of these departments may not understand medical device security. Wrapping them into one role makes for a more efficient position, focusing on the security of medical devices solely.

When a hospital has medical device security engineers separate from biomedical engineers the security focus for these employees with be higher. This will benefit the level of protection at the organizational level.

The Importance of Awareness and Security Updates

As of 2019, more than 32 million patient records have been infringed, according to the Protenus Breach Barometer. Many of these violations were due to hackers. The industry has been prone to phishing and ransomware, reports show.

As security measures are increasing, the tools used to combat these issues may not be as effective as security leaders hope. Threats and concerns are constantly rising; however, the healthcare industry still scrambles to keep up the pace. Medical device attacks from hackers are quickly becoming a major security concern. Anything wireless has the potential to be compromised.

Whether it be pacemakers, cardiac defibrillators or any wireless hospital equipment—all these types of devices are at risk. Industry and manufacturers alike must work towards making these devices safer while complying with the FDA guidelines. Otherwise, the risk for attacks will continue to grow as technology continues to advance.

Source : https://www.medtechintelligence.com/column/implanted-medical-devices-and-vulnerabilities-to-hackers/

Why Software-Powered Electronics Manufacturing is Advancing the Medtech Industry by Sudeep Goswani

Electronics manufacturing is experiencing radical change for the first time in decades. While the traditional engineering cycle from design to manufacturing can take months or even years, smart manufacturing practices are empowering engineers to bring their designs from concept to prototype more quickly, thus, enabling them to experiment and innovate more often. Driven by aggressive deployment and production cycles, engineers developing prototype electronics for critical systems in medical technology need the ability to rapidly iterate on their designs.

The medical technology industry is growing rapidly and is a critical part of the larger global healthcare field. The global medical technology industry’s market size (as of 2019) is $430 billion, according to Statistica. As medical treatments, systems operations and preventative care become more technology-based, there is a higher demand for electronics prototypes and the use of materials and assembly methods like 3-D printing and printed circuit boards (PCBs). These products require fast development and turnover to meet the highly competitive, growing medical technology market. To meet these demands, medical device engineers require the ability to generate high-quality prototypes for complex electronics products in record speed—a process that can be achieved more quickly through the process of software-powered PCBA (printed circuit board assembly) manufacturing.

Sudeep Goswani, Tempo Automation

How Does PCBA Play a Role in Medical Technology?

From technology like electroceuticals (referring to the concept of delivering pharmaceuticals to patients via small electronic implants) to new sensors-based wearables that track the activity of patients, medical technology is evolving to rely more heavily on embedded computing to provide new levels of functionality. Over the last couple of years, a number of innovative medical devices have been introduced to the market to aid medical practitioners in performing testing that was traditionally limited to large medical facilities.

At the heart of the advancements being made in the medtech field are the PCBs found within electronic medical devices, much of which have to do with the flexibility, durability and reliability of PCBAs. And as technology has matured in healthcare, PCBs have become increasingly important to the development of new devices; the internal computers are often so small that they require high-density interconnect (HDI) PCBs to properly function. These PCBs can be found in anything from a pacemaker or heart monitor, to MRI and CT scanner equipment.

It is imperative for engineers working on new medical technology to be able to produce more iterations of their designs with efficiency, accuracy and speed. Many of these life-saving medical devices (i.e., pacemakers), require several iterations of prototype and design, as well as thorough QC checks before they can hit the market. The faster that engineers and designers from medtech manufacturing companies are able to receive prototypes back and learn from data provided to them through the manufacturing process, the faster they are able to make valuable changes that ultimately create better end-products and further advance the medtech field.

The legacy contract manufacturing (CM) process for PCBA utilizes what is known as the black box approach—a slow process that offers little-to-no insight on the outcome of their designs prior to manufacture and one that can take weeks or months to complete. With a black box approach, PCBA design and manufacturing requires considerable time to make corrections to the design files before the board layout specifications are synchronized with the equipment capabilities and processes of the CM. A white box approach, on the other hand, utilizes software-powered electronics manufacturing and data to fill the communications gap between engineers and CMs by providing information gleaned directly from the connected factory floor and software to accelerate the end-to-end PCBA process.

Advancing Medtech Electronics with Smart Manufacturing

The white box approach leverages software and smart manufacturing, using a network of connected devices on both the front and back end of the PCBA process to automate the flow of information in a continuous cycle of design, build and test. A PCBA smart factory that connects customer engagement, order processing, parts sourcing, factory operations, and shipment of finished PCBAs into one continuous cycle is the future of prototype electronics manufacturing for medtech and other industries. The ability to build and deliver high complexity PCBAs in just days instead of the weeks typical of other manufacturers often cuts the total project time in half, and by leveraging software on both the user front-end for quoting and ordering, and on the backend for factory operations, a smart factory is able to create an unbroken data flow from customer to manufacturer.

GE Healthcare is one example of the power of smart manufacturing in accelerating the production of PCBA for medical product design. The GE Healthcare Microscopy Imaging Systems team needed to manufacture a set of complex designs and construction and programming of a test fixture for design testing. For GE Healthcare, quality and precision are very important, as the products they make contribute to life-saving discoveries by hospitals, research laboratories, institutes and universities. These high standards can only be achieved when their engineering teams have time to quickly fail and iterate.

Before working with a smart factory CM, the team had to routinely wait up to an entire month to receive finished boards back and even longer for new designs. These long wait times compromised their chances of meeting design deadlines. Using a software-based smart PCBA manufacturing approach, GE Healthcare was able to receive complex boards back within five days, which significantly shortened the “fail and iterate” process. Being able to fail faster had a direct impact on the team’s timeline and resulted in a better-quality prototype—for both the testing and revision process as well as the final product.

Due to strict compliance rules from the FDA and other medical regulatory bodies, PCBA for medical devices requires the ability to design, build and test until the device meets a set of strict performance requirements such as reliability, quality, safety and other factors. Innovation in medical device development is guided by functionality and capabilities; however, cost-effectiveness is also a consideration. Therefore, developing the highest quality boards possible that will result in high production yield rates should also be a priority for your design. Engineering teams should consider switching to a new model of design and development for PCBAs that leverage software and automated systems to not only provide PCBs back quicker but also offer data that can provide important insight into their design process and product lifecycle.

According to a report from iConnect007, the global PCB market is expected to reach $89.7 billion within the next five years. The medical device industry is one of the key players in the PCB market and attributes a great deal to the recent growth. The implementation of PCBs in medical devices and the need for faster PCBA timelines will continue to expand as the technology grows. To help further expedite this growth, engineering teams and key decision-makers alike for medtech manufacturers should consider a more streamlined approach to electronics development using software-powered smart manufacturing.

Source: https://www.medtechintelligence.com/column/why-software-powered-electronics-manufacturing-is-advancing-the-medtech-industry/

How medical technology is making a big difference for your health by Amy Osmond Cook Health & Wellness

1.jpg

Technology is an integral part of daily life, from constant entertainment at the fingertips to the ability to communicate with family and friends across the globe with the touch of a button.

There seems to be no end to the usefulness of ever-evolving technology, even beyond being able to binge watch your favorite sitcom or take crystal-clear selfies and transmit them to the world.

While you’re busy enjoying your various devices and gadgets, you may not realize the health benefits you can get from them. If your favorite pastime is looking at your reflection in your phone’s camera, even that can keep you healthy.

Here are a few ways that technology can improve your health:

Telemedicine

Advances in technology have improved access to healthcare for people who are unable to visit the doctor. People may avoid a trip to the doctor’s office because of time constraints, distance, or even the inconvenience. The ability to connect with a physician online can make it easier to get diagnosed quickly, making the process more efficient for everyone involved.

“Seniors can have trouble getting access to healthcare if they have limited mobility, restrictive finances, or other difficulties that prevent them from visiting the doctor,” says Sarah Hilton, a registered nurse. “In some cases, technology can help bridge the gap by allowing doctors to connect online with patients in their home.”

Remote monitoring

Along with initial diagnoses for patients, technology allows doctors to provide continued care without frequent visits for patients who need to be monitored. One study showed that patients with diabetes who were remotely monitored by their doctors had better outcomes and management of their condition. The monitoring appeared to help patients take medication on time, and doctors also managed cases more actively.

Preventing outbreaks

Food recalls due to foodborne illness make the news every year. People may not realize that the behind-the-scenes science involved in tracking foodborne illnesses is quite advanced. By studying the DNA of germs, scientists are able to track the spread of germs like listeria. Scientists can determine where the illness originated and improve treatment by letting doctors know about specific illnesses affecting their region.

Electronic health records

Electronic health records might not seem like a very exciting benefit of technology, but they can have a huge impact on a person’s health. Not only do these records streamline information, but they also improve access to the records for both the doctor and the patient. Accurate, accessible records help patients advocate for their health and give the doctor a better big picture of the patient’s history, which can reduce mistakes.

There are a lot of reasons to appreciate the advancement of technology, and your health is a big one. The next time you want to skip the doctor’s office because you don’t have time in your busy day, consider avoiding the line by taking advantage of technology and visiting on your computer.

Source: https://www.heraldextra.com/momclick/health-and-fitness/health-and-wellness-column/how-medical-technology-is-making-a-big-difference-for-your/article_e4cd6966-60b2-5e72-a86e-e5e773b3e5ec.html

Koch Industries bets on tech: ‘Do it or we’ll end up in the Dumpster’ by Tom Maloney

1.jpg

It’s not quite what you’d expect from a Koch. Certainly not while speaking before the gray-haired Rotary Club in Wichita, Kan.

But there was Chase Koch, scion of one of America’s mightiest private industrial dynasties — a family revered by the political right, reviled by the left and feared by just about everyone — joking about his knockabout years down in Texas.

It was back in the early 2000s, Chase said, after he graduated with a marketing degree from the proudly anti-Ivy League Texas A&M. (His father, Charles, and uncle, David, studied engineering at MIT, as did his grandfather Fred.) Reluctant to tap the Koch network for a job, he was hunting for work, banging out Led Zeppelin covers with his band and, as he put it, “screwing around in Austin.”

Times change — and, with time, the Kochs do too. Chase, 42, now sits on the board of Koch Industries and is president of Koch Disruptive Technologies, the conglomerate’s venture capital arm. He’s at the sharp edge of efforts to prepare for a knowledge-based future in which cheap computers, data and artificial intelligence might threaten the firm’s dominance.

He’s also positioned to control one of the world’s most powerful closely held companies, and he represents the future of the conservative political network that has put the Kochs among the country’s most influential families.

Few people are aware of just how big the Koch empire is or the industries it inhabits. Much as Warren Buffett grew Berkshire Hathaway Inc. from its textile-mill roots, Koch Industries keeps about 90% of its profit and pumps the money back into its businesses or buys new ones. It’s now a sprawling network of subsidiaries reporting back to headquarters in Wichita. They include forestry products (Georgia-Pacific), fertilizer (Koch Ag & Energy Solutions), fabrics (Invista), commodities trading (Koch Supply & Trading) and ranching (Matador Cattle).

The brothers invested well. The $21-million company that Charles joined in 1961 is now worth about $139 billion, a 662,000% return, or roughly 16% annually over almost six decades. Charles and David own about 84% of the company. (Elaine Marshall owns most of the rest, gaining control of the stake after the 2006 death of her husband, E. Pierce Marshall.)

Industrial empire

Koch subsidiaries make a wide range of products and investments.

  • Flint Hills Resources: Gasoline, ethanol, plastics and other chemicals. Owns and operates pipelines.

    Georgia-Pacific: Foresty and building products, including packaging, drywall and plywood. Paper product brands include Brawny, Dixie and AngelSoft.

    Guardian: Produces glass for buildings, automobiles and technical applications.

    Invista: Chemicals, polymers, fibers and fabrics.

    Koch Ag & Energy Solutions: Fertilizers, methanol and natural-gas supply.

    Koch Engineered Solutions: Industrial-process and pollution-control products.

    Koch Disruptive Technologies: Venture capital subsidiary with investments in medical technologies, hybrid cloud computing and metal 3-D printing.

    Koch Equity Development: Private equity arm with investments in enterprise software and network services.

    Koch Supply & Trading: Trading arm active in oil, refined products, gas, power, renewables, metals, freight and derivatives.

    Matador Cattle Co.: Owns more than 460,000 acres of land and 12,000 head of cattle.

Historically, these investments were in industrial assets — refineries, chemical plants, sawmills.

But over the last few years, they’ve been more futuristic, especially in the venture capital arm led by Chase Koch. The conglomerate has invested billions of dollars in software, network technology, big data, AI, medical technology and 3-D printing.

“It’s actually really smart for them to do this,” said Hans Swildens, chief executive of Industry Ventures, which manages more than $3.4 billion of institutional capital. “If you owned a large number of industrial businesses, and you were looking at all the new technologies that were coming out and how they would affect your business, the best thing that you can do is embrace those.”

Jim Hannan, an executive vice president who oversees about half of Koch Industries’ subsidiaries, said tech “has led to a much more common set of issues and opportunities across all our businesses.”

At the same time, big industrials are struggling to grow.

“We are rapidly moving to a digital economy,” said Nick Heymann of William Blair & Co. “Most of the net worth in the last 20 years in this country has been created outside tangible manufacturing businesses.”

For Charles Koch, it was a question of survival. At a 2017 leadership meeting, he pushed his managers to embrace technology and prepare for a knowledge-based future. His message: “Do it or we’ll end up in the Dumpster.”

Falling technology costs are generating new threats to established industries.

There’s “a level of competition that these players did not face,” said Sanjay Aggarwal of Boston-based venture capital fund F-Prime Capital. “Now you can have start-ups out of a garage building an autonomous vehicle. That was just not possible earlier.”

Cheap computing power and data will fundamentally change every industry, said Koch Industries’ chief financial officer, Steve Feilmeier. The firm said it has invested more than $17 billion in technology companies since 2013, with big bets in cloud computing and enterprise data analytics. Investments have included acquisitions as well as strategic stakes.

New Koch

Koch Industries has invested more than $17 billion in tech companies in recent years.

  • InSightec: MRI-guided focused ultrasound

    Genesis Advanced Technology: Robot actuators & gearing

    Mesosphere: Cloud computing software & integration

    Bittware: Network hardware

    Nistica: Network hardware

    Infor Enterprise Applications: Enterprise software

    Desktop Metal: 3-D metal printing

    Windgap Medical: Drug autoinjectors

    Molex: Electronics components

If it’s going to be disrupted by a new technology, Koch wants to be doing the disrupting and “investing in it in a way where we better understand it,” Feilmeier said.

The focus on tech isn’t as big a shift as it appears, said Christopher Leonard, author of “Kochland,” a just-released book about the dynasty.

“If you go back to the 1970s, this company was a knowledge company,” he said. “Yes, they owned oil refineries, but they also filled the basement with IBM computers to study the crude-oil market, the gasoline market, to figure out how to run the refineries at the most optimum level.”

Data analytics have been embedded in the Koch DNA for decades, Leonard said. “I’m not at all surprised that they’re making bigger moves into that space. It builds on their expertise.”

Trying to reposition a huge industrial conglomerate around digital technology doesn’t always have a happy ending.

General Electric Co. “made this big effort and got over its ski tips to make itself the platform for industrial digital analytics, and it got way more expensive more quickly” than former CEO Jeff Immelt anticipated, William Blair’s Heymann said.

Byron Trott, the founder of merchant bank BDT Capital Partners, who has worked with Koch Industries for more than 25 years and advised on several acquisitions, doesn’t see the Kochs’ company running into the same problems. GE faced short-term pressures that come with being publicly traded, he said, while “Koch is doing this because they are really, really good at thinking long term.”

Chase Koch’s group has made some of the more ambitious bets outside Koch Industries’ traditional areas of expertise, such as investing in InSightec Ltd., a manufacturer of ultrasound-based surgical tools that can eliminate the need for incisions. He’s the only member of the family from his generation that works at the company. His sister Elizabeth Koch runs a publishing house, Catapult Books, and David’s children are much younger.

Still, Chase took a somewhat unconventional path.

After graduating from Texas A&M, he spent several years in Austin playing in a band covering Led Zeppelin, Phish and the Grateful Dead, and trying to find his way in the city’s tech start-up scene. Although he previously held summer jobs at Koch, including his first at a cattle ranch at age 15, he spent the years after graduation avoiding his father’s shadow.

“I was too proud to tap into the Koch network,” he told the Wichita Rotarians.

Although he was schooled in his family’s politics from a young age — he recalls Saturdays as a 6-year-old listening to books on tape by Milton Friedman — it’s unclear whether he shares the political philosophy of his father and of his uncle, who ran for vice president as the Libertarian Party nominee in 1980.

“I start with the idea that to learn and grow, you’ve got to be open to other people’s ideas,” Chase Koch told Politico last year. Politics, while important, is “not at all what I’m passionate about.”

That raises questions about what will become of the Koch political network, which gives his father outsize influence in the United States. “There is no comparison for any CEO in corporate America in terms of political influence when compared to Charles Koch,” Leonard said.

The Kochs sponsor candidates, think tanks, advocacy groups and academic groups pushing a conservative, free-market agenda.

Recently, there have been disagreements with the Republican Party under President Trump on issues such as free trade and immigration. Americans for Prosperity, the Kochs’ primary political advocacy group, is shifting focus toward “finding nonpartisan solutions,” according to a June memo, and it’s prepared to support candidates who get things done regardless of party.

In July, the Kochs partnered with liberal investor and philanthropist George Soros to found the Quincy Institute for Responsible Statecraft, a think tank dedicated to promoting peaceful U.S. foreign policy.

Leonard said he isn’t convinced the moves constitute a real change to the Kochs’ political goals.

“It feels like an adaptable reaction to the moment,” he said, “even as Koch keeps its eye on the long-term strategy of doing one thing, which is constraining the reach of the federal government, dismantling the administrative state and pushing back the reach of government as far as possible.”

The political network is “exactly like the corporation,” he said. “It’s run with a long-term view. It has strategic patience.”

When Chase returned to Wichita to rejoin Koch Industries after his years in Austin, he began a rotation of high-level jobs, including stints in mergers and acquisitions, tax structuring, agronomics and trading. It was designed as an MBA-like experience to familiarize him with various parts of the operation.

Koch Industries won’t detail its succession plan beyond saying that one is in place and that roles are filled by those most qualified.

If Chase eventually succeeds his father in running the firm and the political network, he’ll become one of the country’s most influential people.

Source: https://www.latimes.com/business/story/2019-08-16/charles-koch-son-steers-koch-industries-toward-tech

Artificial intelligence could improve healthcare for all—unless it doesn’t by Jeremy Hsu

This story was originally published on Undark magazine and has been republished here with permission.

You could be forgiven for thinking that AI will soon replace human physicians based on headlines such as “The AI Doctor Will See You Now,” “Your Future Doctor May Not Be Human,” and “This AI Just Beat Human Doctors on a Clinical Exam.” But experts say the reality is more of a collaboration than an ousting: Patients could soon find their lives partly in the hands of AI services working alongside human clinicians.

There is no shortage of optimism about AI in the medical community. But many also caution the hype surrounding AI has yet to be realized in real clinical settings. There are also different visions for how AI services could make the biggest impact. And it’s still unclear whether AI will improve the lives of patients or just the bottom line for Silicon Valley companies, healthcare organizations, and insurers.

“I think that all our patients should actually want AI technologies to be brought to bear on weaknesses in the healthcare system, but we need to do it in a non-Silicon Valley hype way,” says Isaac Kohane, a biomedical informatics researcher at Harvard Medical School.

If AI works as promised, it could democratize healthcare by boosting access for underserved communities and lowering costs—a boon in the United States, which ranks poorly on many health measures despite an average annual healthcare cost of $10,739 per person. AI systems could free overworked doctors and reduce the risk of medical errors that may kill tens of thousands, if not hundreds of thousands, of U.S. patients each year. And in many countries with national physician shortages, such as China where overcrowded urban hospitals’ outpatient departments may see up to 10,000 people per day, such technologies don’t need perfect accuracy to prove helpful.

But critics point out that all that promise could vanish if the rush to implement AI tramples patient privacy rights, overlooks biases and limitations, or fails to deploy services in a way that improves health outcomes for most people.

“In the same way that technologies can close disparities, they can exacerbate disparities,” says Jayanth Komarneni, founder and chair of the Human Diagnosis Project (Human Dx), a public benefit corporation focused on crowdsourcing medical expertise. “And nothing has that ability to exacerbate disparities like AI.”

Today, the most popular AI techniques are machine learning and its younger cousin, deep learning. Unlike computer programs that rigidly follow rules written by humans, both machine learning and deep learning algorithms can look at a data set, learn from it, and make new predictions. Deep learning in particular can make impressive predictions by discovering data patterns that people might miss.

But to make the most of these predictions in healthcare, AI can’t go at it alone. Rather, humans still must help make decisions that can have major health and financial consequences. Because AI systems lack the general intelligence of humans, they can make baffling predictions that could prove harmful if physicians and hospitals unquestioningly follow them.

The classic example comes from Rich Caruana, a senior researcher at Microsoft Research, as he explained in Engineering and Technologymagazine last year. In the 1990s, Caruana worked on a project that tried using an earlier form of machine learning to predict whether a patient with pneumonia was a low-risk or a high-risk case. But trouble arose when the machine learning model tried to predict the case for asthma sufferers, who are high-risk because their preexisting breathing difficulties make them vulnerable to pneumonia. The model pegged these patients as low-risk, requiring minor intervention rather than hospitalization—something a human expert never would have done.

If you follow the model blindly, says Kenneth Jung, a research scientist at the Stanford Center for Biomedical Informatics Research, “then you’re hosed. Because the model is saying: ‘Oh, this kid with asthma came in and they got pneumonia, but we don’t need to worry about them, and we’re sending them home with some antibiotics.'”

Deep-learning predictions can also fail if they encounter unusual data points, such as unique medical cases, for the first time, or when they learn peculiar patterns in specific data sets that do not generalize well to new medical cases.

The AI predictions do best when applied to massive data sets, such as in China, which has an advantage in training AI systems thanks to access to large populations and patient data. In February, the journal Nature Medicine published a study from researchers based in San Diego and Guangzhou, China, that showed promise in diagnosing many common childhood diseases based on the electronic health records of more than 567,000 children.

But even large data sets can pose problems, particularly when researchers try to apply their algorithm to a new population. In theNature Medicine study, all of the half million patients came from one medical center in Guangzhou, which means there is no guarantee the diagnostic lessons learned from training on that data set would apply to pediatric cases elsewhere. Each medical center may attract its own unique set of patients—a hospital known for its cardiovascular center, for instance, may attract more critical heart conditions. And findings from a Guangzhou hospital that mostly attracts ethnic Chinese patients may not translate to one in Shanghai with a higher number of foreign-born, non-Chinese patients.

(CAPTION: In this 2017 TEDx Talk, Shinjini Kundu of Johns Hopkins Hospital explains how AI tools have the potential to glean more from medical images than doctors alone can—including predicting diseases before patients show symptoms.)

This extrapolation will prove difficult in other situations as well. For example, says Marzyeh Ghassemi, a computer scientist and biomedical engineer at the University of Toronto, say you have 40,000 ICU patients at Beth Israel Deaconess Medical Center—that’s just one hospital in one city. “And so I have all these papers that have done predictions with this data. Does that work with another hospital in Boston? Maybe. Does it work for a hospital in another state? Would it work in another country? We don’t know.”

While AI models may not work in every case, Ghassemi thinks the technology is still worth exploring. “I am very much in favor of taking these models from the bench to the bedside,” she says, “but with really aggressive precautionary steps.”

Those steps need to exist throughout AI development and deployment, says I. Glenn Cohen, a law professor at Harvard University and a leader for the Project on Precision Medicine, Artificial Intelligence, and the Law. This may involve verifying the accuracy and transparency of AI predictions. And during data collection, researchers will also need to protect patient privacy and ask for consent to use patient data for training AI.

The consent issue comes up again when the AI model is ready for experimental clinical testing with real patients. “Do patients need to be told you’re using the algorithm on them, and does it matter whether the AI is completely guiding care or partly guiding care?” Cohen asks. “There is really very little thinking on these questions.”

Ghassemi also advocates for frequently auditing AI algorithms to ensure fairness and accuracy across different groups of people based on ethnicity, gender, age, and health insurance. That’s important given how AI applications in other fields have already shown that they can easily pick up biases.

After all those steps, the people and companies providing AI services will need to sort out legal liability in the case of inevitable mistakes. And unlike most medical devices, which usually need just one regulatory approval, AI services may require additional review whenever they learn from new data.

Some regulatory agencies are rethinking how to assess healthcare AI. In April, the U.S. Food and Drug Administration (FDA) released a discussion paper to get public feedback about how to update the relevant regulatory review. “What we are continuously trying to do here is get back to our goal of giving people access to technologies, but we’re also realizing that our current methods don’t quite work well,” says Bakul Patel, director for digital health at the FDA. “That’s why we need to look at a holistic approach of the whole product life cycle.”

In addition to issues surrounding access, privacy, and regulations, it also isn’t clear just who stands to benefit the most from AI healthcare services. There are already healthcare disparities: According to the World Bank and the World Health Organization, half of the globe’s population lacks access to essential healthcare services, and nearly 100 million people are pushed into extreme poverty by healthcare expenses. Depending on how it is deployed, AI could either improve these inequalities, or make them worse.

“A lot of the AI discussion has been about how to democratize healthcare, and I want to see that happening,” says Effy Vayena, a bioethicist at the Federal Institute of Technology in Switzerland.

“If you just end up with a fancier service provision to those who could afford good healthcare anyway,” she adds, “I’m not sure if that’s the transformation we’re looking for.”

How this all plays out depends on the different visions for implementing AI. Early development has focused on very narrow diagnostic applications, such as scrutinizing images for hints of skin cancer or nail fungus, or reading chest X-rays. But more recent efforts have tried to diagnose multiple health conditions at once.

In August 2018, Moorfields Eye Hospital in the United Kingdom and DeepMind, the London-based AI lab owned by Google’s parent company Alphabet, showed that they had successfully trained an AI system to identify more than 50 eye diseases in scans, which matched the performance of leading experts. Similarly broad ambitions drove the San Diego and Guangzhou study that trained AI to diagnose common ailments among children. The latter wasn’t as good at diagnosing pediatric diseases compared to senior physicians, but it did perform better than some junior physicians.

Such AI systems may not need to outperform the best human experts to help democratize healthcare but simply expand access to current medical standards. Still, so far, many proposed AI applications are focused on improving the current standard of care rather than spreading affordable healthcare around, Cohen says: “Democratizing what we already have would be a much bigger bang for your buck than improving what we have in many areas.”

Accenture, a consulting firm, predicts that top AI applications could save the U.S. economy $150 billion per year by 2026. But it’s unclear if patients and healthcare systems supplemented by taxpayer dollars would benefit, or if more money would simply flow to the tech companies, healthcare providers, and insurers.

“The question of who is going to drive this and who is going to pay for this is an important question,” says Kohane. “Something a bit hallucinatory about all those business plans is that they think they know how it will work out.”

Even if AI services make cost-saving recommendations, human physicians and healthcare organizations may hesitate to take AI advice if they make less money as a result, Kohane cautions. That speaks to the bigger systemic issue of the U.S. health insurers using a fee-for-service model that often rewards physicians and hospitals for adding tests and medical procedures, even when they aren’t needed.

There is another AI opportunity that could improve the quality of care while still leaving most medical diagnoses in the hands of doctors. In his 2019 book “Deep Medicine,” Eric Topol, director and founder of the Scripps Research Translational Institute, talks about creating essentially a supercharged medical Siri—an AI assistant to take notes about the interactions between doctors and their patients, enter those notes in electronic health records, and remind physicians to ask about relevant parts of the patient’s history.

“My aspiration is that we decompress the work of doctors and get rid of their data clerk role, help patients take on more responsibility, and key up the data so it doesn’t take so long to review things,” Topol says.

That “never-forgetful medical assistant or scribe,” says Kohane, would require AI that can automatically track and transcribe multiple voices between physicians and patients. He supports Topol’s idea but adds that most AI applications in development don’t seem to be focused on such assistants. Still, some companies such as Saykara and DeepScribe have developed services along these lines, and even Google teamed up with Stanford University to test a similar “digital scribe” technology.

An AI assistant may sound less exciting than an AI doctor, but it could free up physicians to spend more time with their patients and improve overall quality of care. Family physicians in particular often spend more than half of their working days entering data into electronic health records—a main factor behind physical and emotional burnout, which has dire consequences, including patient deaths.

Ironically, electronic health records were supposed to improve medical care and cut costs by making patient information more accessible. Now Topol and many other experts point to electronic health records as a cautionary tale for the current hype surrounding AI in medicine and healthcare.

The implementation of electronic health records has already created a patchwork system spread among hundreds of private vendors that mainly succeeds in isolating patient data and makes it inaccessible to both physicians and patients. If history is any guide, many tech companies and healthcare organizations will feel the pull to follow similar paths by hoarding medical data for their own AI systems.

One way around this may be to use a collective intelligence system that aggregates and ranks medical expertise from different sources, says Komarneni, who is trying this approach with Human Dx. Backed by major medical organizations such as the American Medical Association, Human Dx has built an online platform for crowdsourcing advice from thousands of physicians on specific medical cases. Komarneni hopes that such a platform could, in theory, also someday include diagnostic advice from many different AI services.

“In the same way that multiple human professionals might look at your case in the future, there is no reason why multiple AI couldn’t do it,” Komarneni says.

As doctors wait for their AI helpers, crowdsourcing projects like Human Dx “could definitely lead to improved diagnostics or even improved recommendations for therapy,” says Topol, who coauthored a 2018 study on a similar platform called Medscape Consult. The paper concluded collective human intelligence could be a “competitive or complementary strategy” to AI in medicine.

But if AI services pass all the tests and real-world checks, they could become significant partners for humans in reshaping modern healthcare.

“There are things that machines will never do well and then others where they’ll be exceeding what any human can do,” Topol says. “So when you put the two together, it’s a very powerful package.”

Source: https://www.fastcompany.com/90384481/artificial-intelligence-could-improve-health-care-for-all-unless-it-doesnt

Psychedelic Medicine Is Coming. The Law Isn’t Ready by Matt Lamkin

In March, the Food and Drug Administration approved esketamine, a drug that produces psychedelic effects, to treat depression—the first psychedelic ever to clear that bar. Meanwhile the FDA has granted "breakthrough therapy" status—a designation that enables fast-tracked research—to study MDMA (also called "ecstasy") as a treatment for post-traumatic stress disorder and psilocybin as a treatment for major depression.

While these and other psychedelic drugs show promise as treatments for specific illnesses, FDA approval means doctors could also prescribe them for other, "off-label" purposes—including enhancing the quality of life of people who do not suffer from any disorder. Hence if MDMA gains approval as a treatment for PTSD, psychiatrists could prescribe the drug for very different purposes. Indeed, before the federal government banned MDMA, therapists reported striking success in using MDMA to improve the quality of intimate relationships. Recent research bolsters these claims, finding that the drug enhances emotional empathy, increases feelings of closeness, and promotes thoughtfulness and contemplativeness.‌

Similarly, while psilocybin has shown potential as a treatment for depression and anxiety, physicians could also prescribe the drug to promote the well-being of healthy individuals. When researchers at Johns Hopkins gave psilocybin to healthy participants with no history of hallucinogen use, nearly eighty percent reported that their experiences "increased their current sense of personal well-being or life satisfaction 'moderately' or 'very much'"—effects that persisted for more than a year.‌

Yet while the FDA generally does not regulate physicians' prescribing practices, a federal law called the Controlled Substances Act bars them from writing prescriptions without a "legitimate medical purpose." Although this prohibition aims to prevent doctors from acting as drug traffickers, the law does not explain which purposes qualify as "legitimate," nor how to distinguish valid prescriptions from those that merely enable patients' illicit drug abuse.‌

Would prescribing a psychedelic drug simply to promote empathy or increase "life satisfaction" fall within the scope of legitimate medicine—or would these practices render the physician a drug dealer?

To many the answer may seem obvious: to qualify as a "medical" use, a drug must be prescribed to treat an illness. But in fact, medical practice has always included interventions aimed at promoting the well-being of healthy individuals. Doctors provide contraceptives and induce abortions regardless of whether their patients' health is threatened by pregnancy. Plastic surgeons first honed their skills treating the traumas of the First World War, but quickly found themselves reshaping normal bodies and faces simply to enhance appearance.

Today physicians may prescribe stimulants to improve performance at school or minor tranquilizers to help cope with the ordinary stresses of modern life, regardless of whether patients meet the diagnostic criteria of a specific disorder. Indeed, some diagnoses themselves seem little more than thinly-veiled excuses to prescribe drugs simply to enhance quality of life—as when the FDA approved flibanserin to treat a condition called "hypoactive sexual desire disorder," which consists of not desiring sex as much as one would prefer.

At a time when "lifestyle drugs" are marketed as consumer products, it is increasingly difficult to draw a bright line that distinguishes legitimate medical practices from their illicit cousins. If prescribing mind-altering drugs to help healthy people achieve desirable mental states falls within the bounds of legitimate medicine, what is left of the concept of recreational use?

These line-drawing challenges argue for moving away from the drug war's simplistic, punitive approach in favor of more sophisticated strategies for minimizing the risks of psychotropic drugs. For example, when the FDA determines that a drug poses special risks, the agency can require Risk Evaluation and Mitigation Strategies, or "REMS," to promote the safe use of the drug.‌

Rather than focusing on whether a drug is prescribed for a "legitimate medical purpose," REMS can require physicians to register with the FDA and receive special training in order to prescribe the drug. Risk management plans can also stipulate that physicians may only dispense the drug in specific healthcare settings and that a healthcare professional must monitor each patient using the drug.

Similar strategies could be used to mitigate any unique risks posed by psychedelics, without limiting their use to patients suffering from particular disorders. One can imagine a system in which psychedelic drugs could be lawfully prescribed to a healthy individual, but only as part of a guided therapy session led by a specially trained physician. Multiple studies have found that both MDMA and psilocybin can be safely administered in well-supervised clinical settings like these, without harming patients or promoting drug dependence.

The prospect of psychedelic drugs gaining approval as treatments will force a reckoning for our existing system of drug control. While current policies characterize any use of these substances as illicit abuse, acknowledging that these drugs may offer meaningful benefits will require more flexible approaches. Psychedelic medicine may prove to be the thin end of a wedge that moves drug policy away from the elusive goal of eradication in favor of more nuanced strategies that harness the benefits of psychotropic drugs while minimizing their risks.

Source: https://blogs.scientificamerican.com/observations/psychedelic-medicine-is-coming-the-law-isnt-ready/

Former car mechanic graduates from medical school at 47 to address shortage of black doctors by Blake Aslup

When he finally enrolled in the class, he was inspired by his professor, Dr. Micah Watts, to go into medicine.

“He just lit up when he walked into the room,” Allamby told the Plain Dealer. “After the first hour of class, I was like, ‘This is what I want to do. I have to go into medicine.’ It was like a light switched on."

He had wanted to be a doctor as a child, but somewhere during junior or high school he lost sight of it. He also said there were no black doctors as role models for him to emulate.

After earning his business degree with a 3.98 GPA, Allamby started taking basic science courses at Cuyahoga Community College and then earned a second undergraduate degree from Cleveland State University.

In 2015, Allamby dissolved his auto repair business and sold everything off in a day before attending Northeast Ohio Medical University.

“It was like, ‘Finally, I am free of this and I can go after something I’ve always wanted,’" Allamby told the Plain Dealer.

He aced every class in the program and was even appointed to serve as the student representative on the NEOMED Board of Trustees by then-Gov. John Kasich.

Allamby is now completing his three-year residency in emergency medicine at the Cleveland Clinic Akron General Hospital. On top of his personality, academic record and work ethic, his race will benefit his patients.

“There are so many times throughout the different hospitals where I will walk in and (a black patient) will say, ‘Thank God there’s finally a brother here,’" Allamby said. “I think you remove a lot of those barriers when there is a person there who looks like you.”

Although 13% of the U.S. population is black, less than 6% of medical school graduates are black, according to the Association of American Medical Colleges.

Black patients are known to respond better to black doctors. In a 2018 study by the National Bureau of Economic Research, black men were more likely to share details with and heed the advice of black doctors. It found that having a black doctor was more effective at convincing them to get a flu shot than a financial reward.

Allamby hopes to encourage more young black people to become doctors.

“When I speak at a junior high or high school, I tell the kids, ‘Hey, if you are interested in medicine, reach out to me because I will help you as much as I can,’ ” Allamby told the Plain Dealer.

Allamby’s entire family is working to be a part of the medical profession in one way or another. His 23-year-old son, Kyle, is a firefighter who is pursing a paramedic degree. Kyle’s twin sister, Kaye, is studying to be a registered nurse. And Allamby’s wife is a physical therapist.

“I have this big business plan,” Allamby told the Plain Dealer, “where my son will bring in the patient, I will save their life, and my wife will rehab them, and my daughter will take care of them while they’re in the hospital. And then they’ll get a free oil change on discharge.”

Source: https://www.nydailynews.com/news/national/ny-car-mechanic-graduates-medical-school-47-becomes-doctor-20190731-qivassrc5zbi3ct4sei7wza22a-story.html

Iranians say US sanctions blocking life-saving medicine by AP News Agency

With Iran's economy in free fall from "maximum pressure" American sanctions, prices of imported medicines have soared as the national currency tumbled about 70 percent against the dollar.

Even medicines manufactured in Iran are tougher to come by for ordinary Iranians. The cost is out of reach for many in a country where the average monthly salary is equivalent to about $450.

Iran's health system can't keep up and many are blaming US President Donald Trump's punitive campaign for the staggering prices and shortages. The sanctions have hurt ordinary Iranians, sending prices for everything from staples and consumer goods to housing skyward, while raising the spectre of war with the United States.

Taha Shakouri keeps finding remote corners to play in at a Tehran children's charity hospital, unaware that his doctors are running out of chemotherapy medicine needed to treat the eight-year-old boy's liver cancer.

Taha's mother, Laya Taghizadeh, said the hospital provides her son's medication for free - a single treatment would otherwise cost $1,380 at a private hospital. She added the family is deeply grateful to the doctors and the hospital staff.

"We couldn't make it without their support," the 30-year-old woman said. "My husband is a simple grocery store worker and this is a very costly disease."

Amid US sanctions, Iranian Kurds seek jobs in Iraq (2:10)

The Iranian rial has plunged from 32,000 to the dollar at the time of the landmark 2015 nuclear deal between Tehran and world powers to about 120,000 rials to the dollar these days, greatly affecting prices of imported medicines.

The famous 2015 nuclear deal involving Iran and world powers had raised expectations of a better life for many Iranians, free of the chokehold of international sanctions.

The accord lifted international sanctions in exchange for curbs on Iran's nuclear programme, but now the deal has all but unravelled after the US pulled out last year and new and tougher US sanctions were imposed.

'Obvious lie'

While the US insists that medicines and humanitarian goods are exempt from sanctions, restrictions on trade have made many banks and companies across the world hesitant to do business with Iran, fearing punitive measures from Washington. The country is cut off from the international banking system.

Last week, Health Minister Saeed Namaki said budget cuts, because of the drop in crude exports, have dramatically affected his department. The US sanctions have targeted all classes of Iranians, he added.

"The American claims that medicine and medical equipment are not subject to sanctions is a big and obvious lie," Namaki said.

"Our biggest concern is that channels to the outside world are closed," said Dr Arasb Ahmadian, head of the Mahak Children's Hospital, which is run through charity donations and supports some 32,000 under-16s across Iran.

The banking sanctions have blocked transactions, preventing donations from abroad, he said. Transfers of money simply fail, including those approved by the US Treasury.

"Indeed, we are losing hope," said Ahmadian. "Medicines should be purchasable, funding should be available, and lines of credit should be clearly defined in the banking system."

Official reports say Iran produces some 95 percent of the basic medicines it needs and even exports some of the production to neighbouring countries.

Trump threatens to increase sanctions over Iran nuclear programme (2:38)

But when it comes to more sophisticated medication for costly and rare illnesses and medical equipment, Iran depends heavily on imports. And though the state provides healthcare for all, many treatments needed for complicated cases are simply not available. Many prefer to go to private hospitals if they can and avoid long waiting lists at state-run hospitals.

'Punishing' terminally ill

Long lines form every morning in the 13-Aban Pharmacy in central Karimikhan Street, where people come looking for rare medicines for sick family members.

Hamid Reza Mohammadi, 53, spends much of his free time going in search of drugs for his wife and daughter, both of whom suffer from muscular dystrophy.

"Two, three months ago I could easily get the prescription filled in any pharmacy," Mohammadi said, reflecting how quickly things have deteriorated.

Pharmacist Peyman Keyvanfar said many Iranians, with their purchasing power slashed, cannot afford imported medicines and are looking for domestically-manufactured substitutes. "There has been a very sharp increase in the prices of medicines, sometimes up to three to four times for some," he said.

Those who still have some cash often turn to the black market.

Mahmoud Alizadeh, a 23-year-old student, rushed to the shady Nasser-Khosrow Street in southern Tehran when he got word that his mother's multiple sclerosis drug was available there.

"She is just 45-years old, it's too soon to see her so badly paralyzed," he said.

He pays three times more for the drug on the street than he did in May 2018. "I don't know on whom Trump imposed sanctions except that he is punishing terminally ill people here."

Many travel from rural areas to bigger cities in search of drugs for their loved ones.

Hosseingholi Barati, a 48-year-old father of three, came to Tehran from the town of Gonbad Kavus, about 550km northeast of the capital, looking for medication for his leukaemia-stricken wife. He has spent $7,700 so far on her illness.

"It's a huge strain," he said. "I have sold everything I owned and borrowed money from family and friends."

Source: https://www.aljazeera.com/news/2019/07/iranians-sanctions-blocking-life-saving-medicine-190730101235408.html

How tech-infused primary care centers turned One Medical into a $2 billion business by Christina Farr

Two years after leaving the traditional health-care world to lead primary care upstart One Medical, Amir Dan Rubin now faces a clear challenge. With competition heating up, he needs to rapidly expand the business into new areas without sacrificing t…

Two years after leaving the traditional health-care world to lead primary care upstart One Medical, Amir Dan Rubin now faces a clear challenge. With competition heating up, he needs to rapidly expand the business into new areas without sacrificing the luxe service that patients have come to expect.

Founded in 2007 by physician-turned-entrepreneur Tom X Lee, One Medical has become popular in and around its hometown of San Francisco by providing on-demand care and easy mobile booking and by selling its services to big companies who offer access as a perk to employees. Google and SpaceX are among those employers, according to a person familiar with the matter who asked not to be named because the relationships are confidential.

One Medical is taking on a chunk of the $3.5 trillion health-care industry, which is riddled with inefficiencies, impersonal care and old technologies that don’t talk to each other and leave patients struggling to find and track their medical records. The company is trying to modernize the whole process, and asks patients to pay a $199 annual membership fee.

“The vision and the focus is to delight millions,” said Rubin, in a recent interview at One Medical’s San Francisco headquarters. “In health care, almost every stakeholder group is frustrated and so we looked to solve a lot of these needs simultaneously by starting from scratch and putting the member at the center of the experience.”

One Medical has 72 clinics in seven states, and Rubin said he’s focused on pushing into new areas. The company is opening locations in Portland, Oregon, as well as Orange County, California, and Atlanta. It’s also partnering with health systems Providence St. Joseph (in Portland and Orange County) and Advocate Aurora (in Chicago), which should lead to more referrals from doctors at those hospitals. Three more Southern California locations are slated to open in the coming months in close collaboration with the University of California San Diego.

Keeping doctors happy

To fuel its growth, One Medical raised $220million last year in a funding round led by private equity firm Carlyle Group, bringing total capital raised to more than $400 million, which includes early money from Google Ventures (now GV) and venture firm Benchmark. The latest financing valued the company at about $1.5 billion, according to two people familiar with the matter. That valuation has subsequently edged up to closer to $2 billion based on secondary market transactions, said one of the people, who asked not to be named because the terms are private.

Overall, One Medical says it has 4,000 employers now offering the service as a benefit. But there’s a growing number of emerging competitors bidding for these contracts. They include Premise Health, Paladina, Iora Health, and Crossover Health.

One key piece to One Medical’s strategy is to make it an appealing place for doctors to work. It’s not uncommon for physicians in the U.S. to see 30 or more patients a day and keep visits to less than 10 minutes. One Medical limits doctors to 16 a day. The company also built its own medical records technology from the ground up to help doctors manage patient relationships, a big change from the existing systems that medical professionals say aren’t user friendly.

One Medical’s waiting room

One Medical

Providing a service that’s attractive to tech companies gives One Medical a big leg up in going after businesses.

“Historically, you’ve seen a lot of health-care services providers lag behind other consumer-facing industries, and that’s held them back with employers,” said Brian Marcotte, president and CEO of the National Business Group on Health, which represents employers. “They’ve done a better job at One Medical. You can feel it’s different when you walk in the door.”

One Medical is also adding mental health and pediatric services. Its providers are training to treat patients with anxiety and depression, and its clinics have started offering group counseling sessions. Kimber Lockhart, One Medical’s chief technology officer, said these group experiences have proven very popular in tests at various clinics.

Tech for patients

Lockhart’s tech team, with occasional advisory help from the doctors on staff, developed an app — Treat Me Now — for patients to get advice on whether to see a doctor or stay at home. It also has an online appointment scheduling system, and a video tool for patients to consult with physicians.

Even with One Medical’s efforts to apply elements of Silicon Valley into its business, the reality is that it runs a health-care operation, which is expensive to manage and comes with high administrative and overhead costs and loads of regulation. So investors have been told to remain patient about a potential IPO.

Steve Wise, a One Medical backer from Carlyle, addressed the road to profitability in a recent interview, when he explained the long-term vision.

“You wouldn’t think a firm like us would invest in a venture-style company that still loses money,” he said. “But it’s a space we know well and we believe in. We want to be the Starbucks of primary care. ”

Source: https://www.cnbc.com/2019/07/28/one-medical-opening-primary-clinics-in-portland-and-atlanta.html

Opinion: Both politicians and voters need to accept this uncomfortable truth about U.S. health care by Michael Williams

As I spoke recently with colleagues at a conference in Florence, Italy, about health-care innovation, a fundamental truth resurfaced in my mind: the U.S. health-care industry is just that. An industry, an economic force, Big Business, first and foremost. It is a vehicle for returns on investment and the success of our society second.

This is critical to consider as presidential candidates unveil their health-care plans. The candidates and the electorate seem to forget that health care in our country is a huge business.

Health care accounts for almost 20% of GDP and is a, if not the, job engine for the U.S. economy. The sector added 2.8 million jobs between 2006 and 2016, higher than all other sectors, and the Bureau of Labor Statistics projects another 18% growth in health-sector jobs between now and 2026. Big Business indeed.

This basic truth separates us from every other nation whose life expectancy, maternal and infant mortality or incidence of diabetes we’d like to replicate or, better still, outperform.

As politicians and the public they serve grapple with issues such as prescription drug prices, “surprise” medical bills and other health-related issues, I believe it critical that we better understand some of the less visible drivers of these costs so that any proposed solutions have a fighting chance to deflect the health cost curve downward.

As both associate chief medical officer for clinical integration and director of the center for health policy at the University of Virginia, I find that the tension between a profit-driven health-care system and high costs occupies me every day.

The power of the market

Housing prices are market-driven. Car prices are market-driven. Food prices are market-driven.

And so are health-care services. That includes physician fees, prescription drug prices and non-prescription drug prices. So is the case for hospital administrator salaries and medical devices.

All of these goods or services are profit-seeking, and all are motivated to maximize profits and minimize the cost of doing business. All must adhere to sound business principles, or they will fail. None of them disclose their cost drivers, or those things that increase prices. In other words, there are costs that are hidden to consumers that manifest in the final unit prices.

To my knowledge, no one has suggested that Rolls-Royce Motor Cars should price its cars similarly to Ford Motor Company. The invisible hand of “the market” tells Rolls Royce and Ford what their vehicles are worth.

Prescription drugs pricing has different rules

Ford can (it won’t) tell you precisely how much each vehicle costs to produce, including all the component parts that it acquires from other firms. But this is not true of prescription drugs. How much a novel therapeutic costs to develop and bring to market is a proverbial black box. Companies don’t share those numbers. Researchers at the Tufts Center for the Study of Drug Development have estimated the costs to be as high as $2.87 billion, but that number has been hotly debated.

What we can reliably say is that it’s very expensive, and a drug company must produce new drugs to stay in business. The millions of research and development (R&D) dollars invested by Big Pharma has two aims. The first is to bring the “next big thing” to market. The second is to secure the almighty patent for it.

U.S. drug patents typically last 20 years, but according to the legal services website Upcounsel.com: “Due to the rigorous amount of testing that goes into a drug patent, many larger pharmaceutical companies file several patents on the same drug, aiming to extend the 20-year period and block generic competitors from producing the same drug.” As a result, drug firms have 30, 40-plus years to protect their investment from any competition and market forces to lower prices aren’t in play.

Here’s the hidden cost punchline: concurrently, several other drugs in their R&D pipelines fail along the way, resulting in significant product-specific losses. How is a poor firm to stay afloat? Simple, really. Build those costs and losses into the price of the successes. Next thing you know, insulin is nearly $1,500 for a 20-milliliter vial, when that same vial 15 years ago was about $157.

It’s actually a bit more complicated than that, but my point is that business principles drive drug prices because drug companies are businesses. Societal welfare is not the underlying use. This is most true in the U.S., where the public doesn’t purchase most of the pharmaceuticals — private individuals do, albeit through a third party, an insurer. The group purchasing power of 300 million Americans becomes the commercial power of markets. Prices go up.

The cost of doing business, er, treating

I hope that most people would agree that physicians provide a societal good. Whether it’s in the setting of a trusted health confidant, or the doctor whose hands are surgically stopping the bleeding from your spleen after that jerk cut you off on the highway, we physicians pride ourselves on being there for our patients, no matter what, insured or not.

Allow me to state two fundamental facts that often seem to elude patient and policy maker alike. They are inextricably linked, foundational to our national dialogue on health-care costs and oft-ignored: physicians are among the highest earners in America, and we make our money from patients. Not from investment portfolios, or patents. Patients.

Like Ford or pharmaceutical giant Eli Lilly, physician practices also need to achieve a profit margin to remain in business. Similarly, there are hidden-to-consumer costs as well; in this case, education and training. Medical school is the most expensive professional degree money can buy in the U.S. The American Association of Medical Colleges reports that median indebtedness for U.S. medical schools was $200,000.00 in 2018, for the 75% of us who financed our educations rather than paying cash.

Our “R&D” — that is, four years each of college and medical school, three to 11 years of post-doctoral training costs — gets incorporated into our fees. They have to. Just like Ford Motors. Business 101: the cost of doing business must be factored into the price of the good or service.

For policy makers to meaningfully impact the rising costs of U.S. health care, from drugs to bills to and everything in between, they must decide if this is to remain an industry or truly become a social good. If we continue to treat and regulate health care as an industry, we should continue to expect surprise bills and expensive drugs.

It’s not personal, its just…business. The question before the U.S. is: business as usual, or shall we get busy charting a new way of achieving a healthy society? Personally and professionally, I prefer the latter.

Source: https://www.marketwatch.com/story/both-politicians-and-voters-need-to-accept-this-uncomfortable-truth-about-us-health-care-2019-07-24